Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures.

Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP.

Clin Exp Rheumatol. 2010 Nov-Dec;28(6):873-9. Epub 2011 Jan 3.

PMID:
21205463
2.

Inhibition of osteoblast function in vitro by aminobisphosphonates.

Orriss IR, Key ML, Colston KW, Arnett TR.

J Cell Biochem. 2009 Jan 1;106(1):109-18. doi: 10.1002/jcb.21983.

PMID:
19003973
3.

Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment.

Hu L, Han J, Yang X, Wang Y, Pan H, Xu L.

Mol Med Rep. 2016 Oct;14(4):3535-42. doi: 10.3892/mmr.2016.5669. Epub 2016 Aug 24.

4.

Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.

Koch FP, Merkel C, Al-Nawas B, Smeets R, Ziebart T, Walter C, Wagner W.

J Craniomaxillofac Surg. 2011 Dec;39(8):562-9. doi: 10.1016/j.jcms.2010.10.007. Epub 2010 Oct 28.

PMID:
21030265
5.

Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.

Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC.

Cancer Res. 2000 Nov 1;60(21):6001-7.

6.

The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.

Ishtiaq S, Edwards S, Sankaralingam A, Evans BA, Elford C, Frost ML, Fogelman I, Hampson G.

Cytokine. 2015 Feb;71(2):154-60. doi: 10.1016/j.cyto.2014.10.025. Epub 2014 Nov 17.

PMID:
25461393
7.

The effects of zoledronate on the survival and function of human osteoblast-like cells.

Huang KC, Cheng CC, Chuang PY, Yang TY.

BMC Musculoskelet Disord. 2015 Nov 16;16:355. doi: 10.1186/s12891-015-0818-5.

8.

Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.

Corrado A, Cantatore FP, Grano M, Colucci S.

Clin Rheumatol. 2005 Sep;24(5):527-34. Epub 2005 Aug 10.

PMID:
16091841
9.

Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.

Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD.

Eur J Pharmacol. 2008 Dec 14;600(1-3):140-7. doi: 10.1016/j.ejphar.2008.10.031. Epub 2008 Oct 21.

PMID:
18973752
10.

Effects of pamidronate on human alveolar osteoblasts in vitro.

Marolt D, Cozin M, Vunjak-Novakovic G, Cremers S, Landesberg R.

J Oral Maxillofac Surg. 2012 May;70(5):1081-92. doi: 10.1016/j.joms.2011.05.002.

11.

Long-term effects of neridronate on human osteoblastic cell cultures.

Frediani B, Spreafico A, Capperucci C, Chellini F, Gambera D, Ferrata P, Baldi F, Falsetti P, Santucci A, Bocchi L, Marcolongo R.

Bone. 2004 Oct;35(4):859-69.

PMID:
15454093
12.

Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.

Zara S, De Colli M, di Giacomo V, Zizzari VL, Di Nisio C, Di Tore U, Salini V, Gallorini M, Tetè S, Cataldi A.

Clin Oral Investig. 2015 Apr;19(3):601-11. doi: 10.1007/s00784-014-1280-8. Epub 2014 Jul 24.

PMID:
25055744
13.

Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.

Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.

Calcif Tissue Int. 2008 Mar;82(3):191-201. doi: 10.1007/s00223-008-9104-y. Epub 2008 Feb 8.

PMID:
18259679
14.

Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.

Fromigué O, Body JJ.

J Endocrinol Invest. 2002 Jun;25(6):539-46.

PMID:
12109626
15.

Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells.

Bayram H, Kenar H, Taşar F, Hasırcı V.

Int J Oral Maxillofac Surg. 2013 Jan;42(1):140-6. doi: 10.1016/j.ijom.2012.03.026. Epub 2012 May 8.

PMID:
22571861
16.

Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.

Lindtner RA, Tiaden AN, Genelin K, Ebner HL, Manzl C, Klawitter M, Sitte I, von Rechenberg B, Blauth M, Richards PJ.

Osteoporos Int. 2014 Mar;25(3):1151-61. doi: 10.1007/s00198-013-2494-3. Epub 2013 Aug 22.

17.

Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells.

Ribeiro V, Garcia M, Oliveira R, Gomes PS, Colaço B, Fernandes MH.

J Cell Mol Med. 2014 Jan;18(1):27-37. doi: 10.1111/jcmm.12154. Epub 2013 Oct 31.

18.
19.

Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.

Kaiser T, Teufel I, Geiger K, Vater Y, Aicher WK, Klein G, Fehm T.

Breast Cancer Res Treat. 2013 Jul;140(1):35-48. doi: 10.1007/s10549-013-2613-z. Epub 2013 Jun 27.

PMID:
23807419
20.

Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.

Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B.

Oral Dis. 2011 Mar;17(2):194-9. doi: 10.1111/j.1601-0825.2010.01720.x. Epub 2010 Aug 27.

PMID:
20796232

Supplemental Content

Support Center